title: A potent inhibitor of inducible nitric oxide synthase, ONO-1714, a cyclic amidine derivative.
abstract: (1S,5S,6R,7R)-7-Chloro-3-imino-5-methyl-2-azabicyclo[4.1.0]heptane hydrochloride (ONO-1714), a novel cyclic amidine analogue, inhibits human inducible nitric oxide (iNOS) with a K(i) of 1.88 nM and rodent iNOS with similar potency in vitro. ONO-1714 was found to be 10-fold selective for human iNOS over human endothelial NOS (ecNOS). When the inhibitory activity of ONO-1714 was compared for iNOS, it was found to be 451-fold and >20,000-fold more potent than L-NMMA and aminoguanidine (AG), respectively. In terms of human iNOS selectivity, ONO-1714 was approximately 34- and 2-fold more selective for iNOS than L-NMMA and AG, respectively. ONO-1714 inhibited the LPS-induced elevation of plasma nitrate/nitrite in mice with an ID(50) value of 0.010 mg/kg, s.c. The maximum tolerated dose of ONO-1714 was 30 mg/kg, i.v. Thus, ONO-1714 represents one of the most potent iNOS inhibitors in vitro and in vivo to date and has great potentials for use as an inhibitor for clarifying the pathophysiological roles of iNOS and for use as a therapeutic agent.
authors.affiliation: Minase Research Institute, Ono Pharmaceutical Company, Ltd., 3-1-1 Sakurai, Shimamoto, Mishima, Osaka, 618-8585, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Naka
authors.forename: T
authors.initials: T
authors.lastname: Nanbu
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Kamanaka
authors.forename: M
authors.initials: M
authors.lastname: Komeno
authors.forename: R
authors.initials: R
authors.lastname: Yanase
authors.forename: T
authors.initials: T
authors.lastname: Fukutomi
authors.forename: S
authors.initials: S
authors.lastname: Fujimura
authors.forename: H G
authors.initials: HG
authors.lastname: Seo
authors.forename: N
authors.initials: N
authors.lastname: Fujiwara
authors.forename: S
authors.initials: S
authors.lastname: Ohuchida
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Kondo
authors.forename: N
authors.initials: N
authors.lastname: Taniguchi
mesh_terms: D000578:Amidines / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006574:Heterocyclic Compounds, 2-Ring / Q000494:pharmacology; D006801:Humans; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D052247:Nitric Oxide Synthase Type II; D009573:Nitrites / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors
chemical_list: C407360:7-chloro-3-imino-5-methyl-2-azabicyclo(4.1.0)heptane; D000578:Amidines; D004791:Enzyme Inhibitors; D006574:Heterocyclic Compounds, 2-Ring; D009573:Nitrites; D011994:Recombinant Proteins; D009569:Nitric Oxide; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse